| # | Title | Journal | Year | Citations |
|---|
| 1 | Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy | Lancet, The | 2017 | 662 |
| 2 | Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis | Lancet, The | 2018 | 452 |
| 3 | Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure | JAMA - Journal of the American Medical Association | 2016 | 450 |
| 4 | Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial | Lancet, The | 2019 | 408 |
| 5 | Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial | Lancet Diabetes and Endocrinology,the | 2021 | 287 |
| 6 | Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects | Journal of the American Society of Nephrology: JASN | 2017 | 280 |
| 7 | Renoprotective effects of sodium-glucose cotransporter-2 inhibitors | Kidney International | 2018 | 262 |
| 8 | Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials | Lancet Diabetes and Endocrinology,the | 2019 | 223 |
| 9 | SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications | Lancet, The | 2021 | 222 |
| 10 | The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial | Lancet Diabetes and Endocrinology,the | 2015 | 221 |
| 11 | Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis | European Heart Journal | 2018 | 218 |
| 12 | Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups | Circulation | 2019 | 211 |
| 13 | Diagnostic value of imaging in infective endocarditis: a systematic review | Lancet Infectious Diseases, The | 2017 | 205 |
| 14 | Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection | Journal of the American Society of Nephrology: JASN | 2015 | 204 |
| 15 | Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies | Lancet Diabetes and Endocrinology,the | 2019 | 199 |
| 16 | Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes | Diabetes Care | 2015 | 196 |
| 17 | The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics | American Journal of Nephrology | 2017 | 194 |
| 18 | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | American Journal of Nephrology | 2019 | 194 |
| 19 | Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis | Diabetes, Obesity and Metabolism | 2019 | 190 |
| 20 | Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot–Based Methods for Therapeutic Drug Monitoring | Therapeutic Drug Monitoring | 2019 | 188 |
| 21 | Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers | Diabetes, Obesity and Metabolism | 2018 | 180 |
| 22 | Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial | Lancet Diabetes and Endocrinology,the | 2018 | 179 |
| 23 | Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial | Nephrology Dialysis Transplantation | 2020 | 168 |
| 24 | Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial | Lancet Diabetes and Endocrinology,the | 2020 | 166 |
| 25 | The growing world of small heat shock proteins: from structure to functions | Cell Stress and Chaperones | 2017 | 158 |
| 26 | Reducing major risk factors for chronic kidney disease | Kidney International Supplements | 2017 | 155 |
| 27 | Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial | Lancet Diabetes and Endocrinology,the | 2020 | 155 |
| 28 | A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout | Annals of the Rheumatic Diseases | 2009 | 149 |
| 29 | Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial | Journal of the American Society of Nephrology: JASN | 2018 | 148 |
| 30 | Effects of Lowering LDL Cholesterol on Progression of Kidney Disease | Journal of the American Society of Nephrology: JASN | 2014 | 142 |
| 31 | Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study | The Lancet Gastroenterology and Hepatology | 2016 | 140 |
| 32 | Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol | Annals of the Rheumatic Diseases | 2009 | 138 |
| 33 | Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes | JAMA - Journal of the American Medical Association | 2014 | 136 |
| 34 | Proteostasis in cardiac health and disease | Nature Reviews Cardiology | 2017 | 133 |
| 35 | From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics | Clinical Pharmacology and Therapeutics | 2021 | 131 |
| 36 | The glycocalyx—linking albuminuria with renal and cardiovascular disease | Nature Reviews Nephrology | 2015 | 128 |
| 37 | Fosfomycin: Pharmacological, Clinical and Future Perspectives | Antibiotics | 2017 | 127 |
| 38 | Therapeutic Drug Monitoring of Posaconazole: an Update | Current Fungal Infection Reports | 2016 | 126 |
| 39 | Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate | Kidney International | 2018 | 124 |
| 40 | Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus | Circulation | 2019 | 121 |
| 41 | MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells | Journal of Pathology | 2019 | 117 |
| 42 | Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial | Lancet Diabetes and Endocrinology,the | 2015 | 114 |
| 43 | Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function | Clinical Journal of the American Society of Nephrology: CJASN | 2017 | 114 |
| 44 | Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis | Journal of Infection | 2018 | 114 |
| 45 | Voriconazole metabolism is influenced by severe inflammation: a prospective study | Journal of Antimicrobial Chemotherapy | 2017 | 113 |
| 46 | GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials | American Journal of Kidney Diseases | 2014 | 109 |
| 47 | Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial | Journal of the American Society of Nephrology: JASN | 2020 | 106 |
| 48 | 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up | European Journal of Nuclear Medicine and Molecular Imaging | 2018 | 99 |
| 49 | Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials | Circulation | 2022 | 97 |
| 50 | Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets | PLoS ONE | 2015 | 95 |
